Survival Statistics - Revision history

MesotheliomaSupport: Reconcile survival stats with cornerstone page: 15% overall → 12% pleural-specific (SEER 2015-2021), update year to 2026

2026-03-17T20:45:54Z

Reconcile survival stats with cornerstone page: 15% overall → 12% pleural-specific (SEER 2015-2021), update year to 2026

MesotheliomaSupport: Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

2026-03-08T22:37:33Z

Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

Show changes

MesotheliomaSupport: Internal linking: added 5 wiki links

2026-02-20T20:56:38Z

Internal linking: added 5 wiki links

MesotheliomaSupport: Internal linking: added 5 wiki links

2026-02-20T20:53:42Z

Internal linking: added 5 wiki links

MesotheliomaSupport: Internal linking: added 9 wiki links

2026-02-20T20:47:14Z

Internal linking: added 9 wiki links

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:29:26Z

Fix dark mode compatibility: remove problematic background/text colors

Show changes

MesotheliomaSupport: Fixed broken Key Facts table syntax

2026-01-15T05:11:04Z

Fixed broken Key Facts table syntax

← Older revision		Revision as of 05:11, 15 January 2026
Line 35:		Line 35:
	Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.		Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.

	== Key Facts =={\| class="wikitable" style="width:100%; margin~~-top~~:-0~~.5em~~; border-collapse:collapse;"		== Key Facts ==
			{\| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"
	\|-		\|-
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025

MesotheliomaSupport: Fixed gap between Key Facts heading and box

2026-01-15T05:10:25Z

Fixed gap between Key Facts heading and box

← Older revision		Revision as of 05:10, 15 January 2026
Line 35:		Line 35:
	Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.		Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.

	== Key Facts ==		== Key Facts =={\| class="wikitable" style="width:100%; margin-top:-0.5em; border-collapse:collapse;"
	{\| class="wikitable" style="width:100%; margin:0 ~~0 1em 0~~; border-collapse:collapse;"
	\|-		\|-
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025

MesotheliomaSupport: Reduced gap between Key Facts heading and box

2026-01-15T05:09:24Z

Reduced gap between Key Facts heading and box

← Older revision		Revision as of 05:09, 15 January 2026
Line 36:		Line 36:

	== Key Facts ==		== Key Facts ==
			{\| class="wikitable" style="width:100%; margin:0 0 1em 0; border-collapse:collapse;"
	{\| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
	\|-		\|-
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025

MesotheliomaSupport: Fixed text colors for dark mode visibility

2026-01-15T05:07:21Z

Fixed text colors for dark mode visibility

← Older revision		Revision as of 20:45, 17 March 2026
Line 1:		Line 1:
	{{#seo:		{{#seo:
	\|title=Mesothelioma Survival Rates & Statistics ~~2025~~: Complete Prognosis Guide		\|title=Mesothelioma Survival Rates & Statistics 2026: Complete Prognosis Guide
	\|description=Current mesothelioma survival statistics show 15% 5-year survival ~~overall~~. Learn factors affecting prognosis and how treatment advances are improving outcomes.		\|description=Current mesothelioma survival statistics show 12% 5-year survival for pleural mesothelioma (SEER 2015–2021). Learn factors affecting prognosis and how treatment advances are improving outcomes.
	\|keywords=mesothelioma survival rate, mesothelioma prognosis, mesothelioma life expectancy, mesothelioma statistics, mesothelioma survival by stage		\|keywords=mesothelioma survival rate, mesothelioma prognosis, mesothelioma life expectancy, mesothelioma statistics, mesothelioma survival by stage
	\|image=mesothelioma-survival-statistics.jpg		\|image=mesothelioma-survival-statistics.jpg
	\|author=Danziger & De Llano Legal Team		\|author=Danziger & De Llano Legal Team
	\|published_time=2026-01-14		\|published_time=2026-03-17
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
Line 11:		Line 11:
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Survival Statistics		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Survival Statistics
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; " \| Current Data Through ~~2025~~		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; " \| Current Data Through 2026
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6; " \| 5-Year Survival (~~All~~)		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6; " \| 5-Year Survival (Pleural)
	\| style="padding:10px; border-bottom:1px solid #dee2e6; " \| 15%		\| style="padding:10px; border-bottom:1px solid #dee2e6; " \| 12%
	\|-		\|-
	\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6; " \| Localized Stage		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6; " \| Localized Stage
Line 33:		Line 33:
	== Executive Summary ==		== Executive Summary ==

	[[Mesothelioma Survival Rates\|Mesothelioma survival rates]] have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows ~~overall~~ 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]] patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for [[Asbestos Exposure\|asbestos exposure]].		[[Mesothelioma Survival Rates\|Mesothelioma survival rates]] have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data (2015–2021) shows 5-year relative survival of approximately 12% for pleural mesothelioma, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]] patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for [[Asbestos Exposure\|asbestos exposure]].

	== At-a-Glance ==		== At-a-Glance ==
Line 55:		Line 55:
	! style="padding:10px; background:#1a5276; color:white;" \| Finding		! style="padding:10px; background:#1a5276; color:white;" \| Finding
	\|-		\|-
	\| style="padding:10px; border:1px solid #dee2e6;" \| '''~~Overall~~ 5-year ~~relative~~ survival'''		\| style="padding:10px; border:1px solid #dee2e6;" \| '''Pleural mesothelioma 5-year survival'''
	\| style="padding:10px; border:1px solid #dee2e6;" \| 15% across all stages ~~and types~~ (SEER ~~Database, 2025~~; n=~3,200/year)		\| style="padding:10px; border:1px solid #dee2e6;" \| 12% across all stages (SEER 2015–2021; n=~3,200 new diagnoses/year)
	\|-		\|-
	\| style="padding:10px; border:1px solid #dee2e6;" \| '''Localized-stage 5-year survival'''		\| style="padding:10px; border:1px solid #dee2e6;" \| '''Localized-stage 5-year survival'''

← Older revision		Revision as of 20:56, 20 February 2026
Line 57:		Line 57:
	== What Are Current Mesothelioma Survival Rates by Stage? ==		== What Are Current Mesothelioma Survival Rates by Stage? ==

	Stage at diagnosis remains one of the most important prognostic factors for mesothelioma patients.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide-2/ Mesothelioma Cancer Guide], Danziger & De Llano</ref> The SEER database, which represents the most comprehensive cancer statistics in the United States, categorizes survival by localized, regional, and distant disease stages rather than traditional TNM staging.		Stage at diagnosis remains one of the most important prognostic factors for [[Mesothelioma\|mesothelioma]] patients.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide-2/ Mesothelioma Cancer Guide], Danziger & De Llano</ref> The SEER database, which represents the most comprehensive cancer statistics in the United States, categorizes survival by localized, regional, and distant disease stages rather than traditional TNM staging.

	Localized mesothelioma, where the cancer remains confined to the pleura or peritoneum without spread to lymph nodes or distant sites, shows 23% 5-year relative survival.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma], Danziger & De Llano</ref> Regional disease, indicating spread to nearby lymph nodes or adjacent structures, demonstrates 15% 5-year survival. Distant metastatic disease, where cancer has spread to remote organs or distant lymph nodes, shows 11% 5-year survival.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/stages/ Stages of Mesothelioma], Mesothelioma Lawyer Center</ref>		Localized mesothelioma, where the cancer remains confined to the pleura or peritoneum without spread to lymph nodes or distant sites, shows 23% 5-year relative survival.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma], Danziger & De Llano</ref> Regional disease, indicating spread to nearby lymph nodes or adjacent structures, demonstrates 15% 5-year survival. Distant metastatic disease, where cancer has spread to remote organs or distant lymph nodes, shows 11% 5-year survival.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/stages/ Stages of Mesothelioma], Mesothelioma Lawyer Center</ref>
Line 74:		Line 74:
	The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]], arising in the abdominal lining, maintains substantially better prognosis than [[Pleural Mesothelioma\|pleural mesothelioma]] affecting the lung lining.		The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]], arising in the abdominal lining, maintains substantially better prognosis than [[Pleural Mesothelioma\|pleural mesothelioma]] affecting the lung lining.

	'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>		'''[[Peritoneal Mesothelioma]]''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>

	'''[[Pleural Mesothelioma]]''' represents approximately 80% of all cases and carries median survival of 12-21 months depending on stage, histology, and treatment approach.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], Mesothelioma Attorney</ref> However, patients treated at specialized mesothelioma centers achieve significantly better outcomes, with some programs reporting survival rates 2.5 times national averages.		'''[[Pleural Mesothelioma]]''' represents approximately 80% of all cases and carries median survival of 12-21 months depending on stage, histology, and treatment approach.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], Mesothelioma Attorney</ref> However, patients treated at specialized mesothelioma centers achieve significantly better outcomes, with some programs reporting survival rates 2.5 times national averages.
Line 107:		Line 107:
	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have treatment options that weren't available even five years ago, which affects both their medical decisions and their legal strategy."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have [[Treatment Options\|treatment options]] that weren't available even five years ago, which affects both their medical decisions and their legal strategy."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right; " \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; " \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
Line 132:		Line 132:
	'''MD Anderson Cancer Center''' reports peritoneal mesothelioma outcomes with 40% objective response rate and 85% one-year survival using atezolizumab plus bevacizumab.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/treatment/top-cancer-centers/ Top Mesothelioma Treatment Centers], Mesothelioma Lawyer Center</ref> Their Ki-67 biomarker analysis showed patients with Ki-67 ≤9% achieving median survival of 86.6 months versus just 10.3 months for those with Ki-67 >9%.		'''MD Anderson Cancer Center''' reports peritoneal mesothelioma outcomes with 40% objective response rate and 85% one-year survival using atezolizumab plus bevacizumab.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/treatment/top-cancer-centers/ Top Mesothelioma Treatment Centers], Mesothelioma Lawyer Center</ref> Their Ki-67 biomarker analysis showed patients with Ki-67 ≤9% achieving median survival of 86.6 months versus just 10.3 months for those with Ki-67 >9%.

	'''Moffitt Cancer Center''' reports survival rates approximately 2.5 times national averages: 73% one-year and 12% five-year for pleural mesothelioma, with 65% five-year survival for peritoneal disease (increasing to 80% with CRS-HIPEC plus chemotherapy).<ref>[https://mesothelioma.net/mesothelioma-physicians/ Mesothelioma Doctors], Mesothelioma.net</ref>		'''Moffitt Cancer Center''' reports survival rates approximately 2.5 times national averages: 73% one-year and 12% five-year for [[Pleural Mesothelioma\|pleural mesothelioma]], with 65% five-year survival for peritoneal disease (increasing to 80% with CRS-HIPEC plus chemotherapy).<ref>[https://mesothelioma.net/mesothelioma-physicians/ Mesothelioma Doctors], Mesothelioma.net</ref>

	'''Memorial Sloan Kettering''' published the world's largest single-center outcomes study (945 patients) and demonstrated 51% disease control with tazemetostat for BAP1-mutant disease.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/best-centers/ Top Mesothelioma Treatment Centers], Mesothelioma Attorney</ref>		'''Memorial Sloan Kettering''' published the world's largest single-center outcomes study (945 patients) and demonstrated 51% disease control with tazemetostat for BAP1-mutant disease.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/best-centers/ Top Mesothelioma Treatment Centers], Mesothelioma Attorney</ref>
Line 209:		Line 209:
	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "We've seen how financial security allows families to focus on what matters most—time together and access to the best available care. The companies responsible for asbestos exposure should be held accountable, regardless of how long ago the exposure occurred."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "We've seen how financial security allows families to focus on what matters most—time together and access to the best available care. The companies responsible for [[Asbestos Exposure\|asbestos exposure]] should be held accountable, regardless of how long ago the exposure occurred."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right; " \| '''— Michelle Whitman,''' Attorney, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; " \| '''— Michelle Whitman,''' Attorney, Danziger & De Llano

← Older revision		Revision as of 20:53, 20 February 2026
Line 38:		Line 38:
	{\| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"		{\| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"
	\|-		\|-
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: [[Mesothelioma]] Survival Statistics 2025
	\|-		\|-
	\| style="padding:15px; " \|		\| style="padding:15px; " \|
Line 72:		Line 72:
	== How Does Mesothelioma Type Affect Survival? ==		== How Does Mesothelioma Type Affect Survival? ==

	The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> Peritoneal mesothelioma, arising in the abdominal lining, maintains substantially better prognosis than [[Pleural Mesothelioma\|pleural mesothelioma]] affecting the lung lining.		The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]], arising in the abdominal lining, maintains substantially better prognosis than [[Pleural Mesothelioma\|pleural mesothelioma]] affecting the lung lining.

	'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>		'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>

	'''Pleural Mesothelioma''' represents approximately 80% of all cases and carries median survival of 12-21 months depending on stage, histology, and treatment approach.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], Mesothelioma Attorney</ref> However, patients treated at specialized mesothelioma centers achieve significantly better outcomes, with some programs reporting survival rates 2.5 times national averages.		'''[[Pleural Mesothelioma]]''' represents approximately 80% of all cases and carries median survival of 12-21 months depending on stage, histology, and treatment approach.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], Mesothelioma Attorney</ref> However, patients treated at specialized mesothelioma centers achieve significantly better outcomes, with some programs reporting survival rates 2.5 times national averages.

	'''Pericardial and Testicular Mesothelioma''' are rare variants representing less than 3% of cases combined. Testicular mesothelioma paradoxically shows the best prognosis among all types when treated surgically, while pericardial mesothelioma carries poor prognosis due to its location around the heart.<ref>[https://mesothelioma.net/pericardial-mesothelioma/ Pericardial Mesothelioma], Mesothelioma.net</ref>		'''Pericardial and Testicular Mesothelioma''' are rare variants representing less than 3% of cases combined. Testicular mesothelioma paradoxically shows the best prognosis among all types when treated surgically, while pericardial mesothelioma carries poor prognosis due to its location around the heart.<ref>[https://mesothelioma.net/pericardial-mesothelioma/ Pericardial Mesothelioma], Mesothelioma.net</ref>
Line 82:		Line 82:
	== What Role Does Cell Type Play in Prognosis? ==		== What Role Does Cell Type Play in Prognosis? ==

	Mesothelioma cell type (histology) represents another critical prognostic factor that significantly influences treatment options and survival expectations.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref>		Mesothelioma cell type (histology) represents another critical prognostic factor that significantly influences [[Treatment Options\|treatment options]] and survival expectations.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref>

	'''Epithelioid Mesothelioma''' accounts for 50-70% of cases and carries the most favorable prognosis.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/epithelioid/ Epithelial Mesothelioma], Mesothelioma Attorney</ref> Median survival ranges from 14-18 months, with approximately 14% 5-year survival. This cell type responds best to chemotherapy, immunotherapy, and surgical interventions.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/types/epithelial/ Epithelioid Mesothelioma], Mesothelioma Lawyer Center</ref>		'''Epithelioid Mesothelioma''' accounts for 50-70% of cases and carries the most favorable prognosis.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/epithelioid/ Epithelial Mesothelioma], Mesothelioma Attorney</ref> Median survival ranges from 14-18 months, with approximately 14% 5-year survival. This cell type responds best to chemotherapy, immunotherapy, and surgical interventions.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/types/epithelial/ Epithelioid Mesothelioma], Mesothelioma Lawyer Center</ref>
Line 203:		Line 203:
	* '''Personal Injury Lawsuits:''' Against negligent asbestos manufacturers and employers		* '''Personal Injury Lawsuits:''' Against negligent asbestos manufacturers and employers
	* '''Veterans Benefits:''' VA disability compensation, DIC, and healthcare		* '''Veterans Benefits:''' VA disability compensation, DIC, and healthcare
	* '''Workers' Compensation:''' For occupational asbestos exposure		* '''Workers' Compensation:''' For occupational [[Asbestos Exposure\|asbestos exposure]]

	Statutes of limitations vary by state but typically range from 1-6 years from diagnosis.<ref>[https://dandell.com/mesothelioma/mesothelioma-lawsuits-texas/ How Mesothelioma Lawsuits Work], Danziger & De Llano</ref> While improved survival means more time for treatment, it does not extend legal deadlines. Experienced mesothelioma attorneys can pursue compensation while patients focus on treatment and quality of life.<ref>[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], Mesothelioma Attorney</ref>		Statutes of limitations vary by state but typically range from 1-6 years from diagnosis.<ref>[https://dandell.com/mesothelioma/mesothelioma-lawsuits-texas/ How Mesothelioma Lawsuits Work], Danziger & De Llano</ref> While improved survival means more time for treatment, it does not extend legal deadlines. Experienced mesothelioma attorneys can pursue compensation while patients focus on treatment and quality of life.<ref>[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], Mesothelioma Attorney</ref>

← Older revision		Revision as of 20:47, 20 February 2026
Line 9:		Line 9:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Survival Statistics		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Survival Statistics
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; " \| Current Data Through 2025		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; " \| Current Data Through 2025
Line 33:		Line 33:
	== Executive Summary ==		== Executive Summary ==

	Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.		[[Mesothelioma Survival Rates\|Mesothelioma survival rates]] have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Current SEER data shows overall 5-year relative survival of 15%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]] patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/prognosis/ Mesothelioma Prognosis and Outlook], Mesothelioma Lawyer Center</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for [[Asbestos Exposure\|asbestos exposure]].

	== Key Facts ==		== Key Facts ==
Line 65:		Line 65:
	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "Stage at diagnosis significantly influences both treatment options and outcomes. We work to ensure families understand how staging affects not only prognosis but also their legal timeline for pursuing compensation."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; " \| "Stage at diagnosis significantly influences both [[Treatment Options\|treatment options]] and outcomes. We work to ensure families understand how staging affects not only prognosis but also their legal timeline for pursuing compensation."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right; " \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; " \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
Line 72:		Line 72:
	== How Does Mesothelioma Type Affect Survival? ==		== How Does Mesothelioma Type Affect Survival? ==

	The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> Peritoneal mesothelioma, arising in the abdominal lining, maintains substantially better prognosis than pleural mesothelioma affecting the lung lining.		The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> Peritoneal mesothelioma, arising in the abdominal lining, maintains substantially better prognosis than [[Pleural Mesothelioma\|pleural mesothelioma]] affecting the lung lining.

	'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>		'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>
Line 138:		Line 138:
	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px; " \| '''ℹ Specialized Center Advantage''' Patients treated at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes through access to clinical trials, multidisciplinary teams, and high surgical volumes. Over 80 cancer centers in the US are certified for Tumor Treating Fields therapy.		\| style="padding:15px; " \| '''ℹ Specialized Center Advantage''' Patients treated at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes through access to [[Clinical Trials\|clinical trials]], multidisciplinary teams, and high surgical volumes. Over 80 cancer centers in the US are certified for Tumor Treating Fields therapy.
	\|}		\|}

Line 168:		Line 168:
	'''Age at Diagnosis:''' Patients diagnosed before age 50 show 75% one-year survival compared to 44% for those over 65.<ref>[https://mesothelioma.net/mesothelioma-death-rate/ Mesothelioma Death Rate], Mesothelioma.net</ref> Younger patients more often tolerate aggressive multimodal treatment including surgery, improving their long-term outcomes.		'''Age at Diagnosis:''' Patients diagnosed before age 50 show 75% one-year survival compared to 44% for those over 65.<ref>[https://mesothelioma.net/mesothelioma-death-rate/ Mesothelioma Death Rate], Mesothelioma.net</ref> Younger patients more often tolerate aggressive multimodal treatment including surgery, improving their long-term outcomes.

	'''Performance Status:''' Patients with good functional status (ECOG 0-1) consistently demonstrate better treatment tolerance and survival across all mesothelioma types and stages.<ref>[https://dandell.com/mesothelioma-veterans/ Veterans & Mesothelioma Claims], Danziger & De Llano</ref>		'''Performance Status:''' Patients with good functional status (ECOG 0-1) consistently demonstrate better treatment tolerance and survival across all [[Mesothelioma Types\|mesothelioma types]] and stages.<ref>[https://dandell.com/mesothelioma-veterans/ Veterans & Mesothelioma Claims], Danziger & De Llano</ref>

	{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
Line 179:		Line 179:
	== What Emerging Biomarkers Predict Survival? ==		== What Emerging Biomarkers Predict Survival? ==

	Advanced biomarker testing is transforming mesothelioma prognosis from population-based statistics to individualized predictions.<ref>[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>		Advanced biomarker testing is transforming [[Mesothelioma Prognosis\|mesothelioma prognosis]] from population-based statistics to individualized predictions.<ref>[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>

	'''Liquid Biopsy (ctDNA):''' A landmark 2025 Nature Medicine study validated circulating tumor DNA monitoring as a powerful prognostic tool.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref> Patients achieving undetectable ctDNA at cycle 3 day 1 demonstrated median progression-free survival of 19.84 months versus just 1.41 months for those with detectable ctDNA. Those achieving ≥95% ctDNA reduction showed median PFS of 23.26 months versus 1.68 months—a more than 13-fold difference.		'''Liquid Biopsy (ctDNA):''' A landmark 2025 Nature Medicine study validated circulating tumor DNA monitoring as a powerful prognostic tool.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref> Patients achieving undetectable ctDNA at cycle 3 day 1 demonstrated median progression-free survival of 19.84 months versus just 1.41 months for those with detectable ctDNA. Those achieving ≥95% ctDNA reduction showed median PFS of 23.26 months versus 1.68 months—a more than 13-fold difference.

← Older revision		Revision as of 05:07, 15 January 2026
Line 11:		Line 11:
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Survival Statistics		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Survival Statistics
	\|-		\|-
	\| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" \| Current Data Through 2025		\| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic; color:#333333;" \| Current Data Through 2025
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| 5-Year Survival (All)		\| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" \| 5-Year Survival (All)
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 15%		\| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" \| 15%
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| Localized Stage		\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" \| Localized Stage
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 23% (5-year)		\| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" \| 23% (5-year)
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| Peritoneal Type		\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" \| Peritoneal Type
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 65% (5-year)		\| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" \| 65% (5-year)
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| Immunotherapy OS		\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" \| Immunotherapy OS
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 18.1 months median		\| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" \| 18.1 months median
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa;" \| New Treatments		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333;" \| New Treatments
	\| style="padding:10px;" \| 86% disease control (VT3989)		\| style="padding:10px; background:#ffffff; color:#333333;" \| 86% disease control (VT3989)
	\|-		\|-
	\| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" \| [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]		\| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" \| [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
Line 41:		Line 41:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Survival Statistics 2025
	\|-		\|-
	\| style="padding:15px; background:#f8f9fa;" \|		\| style="padding:15px; background:#f8f9fa; color:#333333;" \|
	* '''Overall 5-Year Survival:''' 15% across all stages and types combined		* '''Overall 5-Year Survival:''' 15% across all stages and types combined
	* '''Localized Disease:''' 23% 5-year survival rate when cancer remains contained		* '''Localized Disease:''' 23% 5-year survival rate when cancer remains contained
Line 66:		Line 66:
	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Stage at diagnosis significantly influences both treatment options and outcomes. We work to ensure families understand how staging affects not only prognosis but also their legal timeline for pursuing compensation."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" \| "Stage at diagnosis significantly influences both treatment options and outcomes. We work to ensure families understand how staging affects not only prognosis but also their legal timeline for pursuing compensation."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; color:#333333;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
	\|}		\|}

Line 108:		Line 108:
	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have treatment options that weren't available even five years ago, which affects both their medical decisions and their legal strategy."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" \| "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have treatment options that weren't available even five years ago, which affects both their medical decisions and their legal strategy."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; color:#333333;" \| '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
	\|}		\|}

Line 173:		Line 173:
	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "When my father was diagnosed, we felt overwhelmed by the statistics. What we learned is that every case is different, and getting to a specialized center made all the difference in his care and our family's peace of mind."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" \| "When my father was diagnosed, we felt overwhelmed by the statistics. What we learned is that every case is different, and getting to a specialized center made all the difference in his care and our family's peace of mind."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— David Foster,''' Client Advocate, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; color:#333333;" \| '''— David Foster,''' Client Advocate, Danziger & De Llano
	\|}		\|}

Line 210:		Line 210:
	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "We've seen how financial security allows families to focus on what matters most—time together and access to the best available care. The companies responsible for asbestos exposure should be held accountable, regardless of how long ago the exposure occurred."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" \| "We've seen how financial security allows families to focus on what matters most—time together and access to the best available care. The companies responsible for asbestos exposure should be held accountable, regardless of how long ago the exposure occurred."
	\|-		\|-
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Michelle Whitman,''' Attorney, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right; color:#333333;" \| '''— Michelle Whitman,''' Attorney, Danziger & De Llano
	\|}		\|}